Legislation to Establish a Michigan Rare Disease Advisory Council to be Introduced on Rare Disease Day insurancenewsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insurancenewsnet.com Daily Mail and Mail on Sunday newspapers.
Feb 19, 2021 9:41am
The FDA hit India s Shilpa with an import alert on all but three of its drugs after the company failed to address problems cited in an October warning letter. (Pixabay/qimono)
Just a few months after India-based drugmaker Shilpa Medicare found itself in the FDA s crosshairs, the company now faces a ban on the vast majority of its products in the U.S.
The FDA slapped an import alert on Shilpa Medicare s formulation plant in Telangana, India, according to a notice posted Thursday. The product ban comes on the heels of an FDA warning letter that cited the Indian drugmaker for multiple manufacturing violations.
Pfizer's already gracing headlines worldwide with its COVID-19 vaccine rollout. Now, it's making a big splash in Tampa Bay. The drug giant is opening a “global capability hub” in the city, bringing multiple services including finance, human resources, digital, and sourcing to one office.
Merck and Eisai showed their Keytruda-Lenvima combo could cut the risk of death by 34% over Pfizer’s old standard treatment Sutent in newly diagnosed kidney cancer. While the overall survival showing was very similar to the numbers for three other immuno-oncology cocktails based on Keytruda or Bristol Myers Squibb’s Opdivo, SVB Leerink analyst Daina Graybosch pointed to other efficacy data in crowning the Keytruda-Lenvima pairing as the “clear choice.” But the win is not a done deal at this point, she noted.
AbbVie’s Allergan and its South Korean partner MedyTox have decided to settle the legal battle they waged against Evolus and its own Korean partner Daewoong Pharmaceutical over their wrinkle-lifting drugs. The news came on the heels of a U.S. appeals court s decision to temporarily allow the Evolus pair’s Botox rival, Jeuveau, to stay on the U.S. market as it reviewed an import ban installed by the U.S. International Trade Commission. AbbVie and Medytox abandoned